Biotechnology

Unlocking the Potential of Multi-Omics in Precision Medicine: A Conversation with Kazusa DNA Research Institute

CHIBA, Japan, Dec. 7, 2023 /PRNewswire/ -- The integration of multi-omics approaches offers a comprehensive panorama for advancing our comprehension of biology. It now plays a more important role in understanding the roots of diseases, and in expediting precision medicine and catalyzing advanceme...

2023-12-07 15:37 1592

Valtech Provides Biotechnology and Technology Startup Orientated Valuation Support

HONG KONG, Dec. 7, 2023 /PRNewswire/ -- Valtech Valuation has recently concluded valuations for several projects within the biotechnology and medical technology sector, specifically focusing on genetic engineering. We are honored to have been entrusted with providing valuation opinions to the man...

2023-12-07 10:00 4315

Valtech Provides Biotechnology and Technology Startup Orientated Valuation Support

HONG KONG, Dec. 7, 2023 /PRNewswire/ -- Valtech Valuation has recently concluded valuations for several projects within the biotechnology and medical technology sector, specifically focusing on genetic engineering. We are honored to have been entrusted with providing valuation opinions to the man...

2023-12-07 10:00 1630

Innovent Biologics and Synaffix Expand ADC Collaboration Following Positive Preliminary Clinical Signal from Ongoing Phase 1 Study

ROCKVILLE, M.D. and SUZHOU, China, Dec. 7, 2023 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, metabolic, autoimmune, ophthalmology an...

2023-12-07 09:00 3106

IonOpticks and Newomics broaden chromatography accessibility for Agilent mass specs, with Shimadzu pending

MELBOURNE, Australia, Dec. 6, 2023 /PRNewswire/ -- IonOpticks, the world leader in high performance liquid chromatography for mass spectrometry, is proud to announce an exciting collaboration with Newomics Inc. that has produced an interface solution for their flagship Aurora Series columns and A...

2023-12-07 07:04 1406

GMP cell CDMO I Peace, Inc. obtains accreditation as ISO 17025: 2017 compliant

Starts undertaking quality evaluation and characterization of iPSCs in accordance with ISO standards PALO ALTO, Calif., Dec. 6, 2023 /PRNewswire/ -- Leading GMP cell CDMO I Peace, Inc. (https://www.ipeace.com ), specializing in induced pluripotent stem cells (iPSCs) and ...

2023-12-06 22:30 1198

Antengene Announces XPOVIO® Regulatory Approval in Macau for the Treatment of Relapsed and/or Refractory Multiple Myeloma

* XPOVIO® (selinexor) is the first and only exportin 1 (XPO1) inhibitor approved in Macau. *  XPOVIO® has received regulatory approvals in  42 countries and regions including Mainland ofChina, Taiwan China, Hong Kong China, Macau China, South Korea, Singapore and Australia. SHANGHAI AND HONG ...

2023-12-06 17:00 1675

GC Biopharma's groundbreaking for the plasma fractionation plant in Indonesia

* To commence operation by 2027…with max. 400K liters of plasma production capacity per annum * The first step towards localization of Indonesia's critical medical product YONGIN,South Korea, Dec. 5, 2023 /PRNewswire/ -- GC Biopharma, a South Korean biopharmaceutical company, announced onDece...

2023-12-06 08:56 1433

inQB8 Medical Technologies LLC and Peijia Medical Limited Report Successful First-in-Human (FIH) Implantation of MonarQ Transcatheter Tricuspid Valve Replacement (TTVR) System in The United States of America

WINCHESTER, Mass. and SUZHOU, China, Dec. 5, 2023 /PRNewswire/ -- inQB8 Medical Technologies LLC (inQB8), in partnership with Peijia Medical Limited (Peijia, (9996.HK)),announced that it has successfully implanted the MonarQ Transcatheter Tricuspid Valve (TTV) in a patient suffering from torrenti...

2023-12-05 21:00 1331

Results of three investigator-initiated trials on cadonilimab (PD-1/CTLA-4) for G/GEJC, pMMR/MSS mCRC, and HCC neoadjuvant therapy published at ESMO Asia 2023

First-line therapy for gastric cancer and metastatic colorectal cancer, neoadjuvant therapy for hepatocellular carcinoma HONGKONG, Dec. 5, 2023  /PRNewswire/ -- Akeso (9926.HK) published results from three investigator-initiated trials (IITs) of its bispecific IO drug, cadonilimab (a PD-1/CTLA-4...

2023-12-05 21:00 1118

Ascletis Announces Initiation of Phase III Clinical Trial of ASC40 (Denifanstat) for Treatment of Acne

--The Phase III clinical trial of ASC40 for moderate to severe acne vulgaris will enroll 480 subjects --The protocol of Phase III clinical trial has been agreed by Center for Drug Evaluation, National Medical Products Administration and obtained the approval from Institutional Review Board of Hu...

2023-12-05 16:50 1534

J INTS BIO Gives Presentation of Phase 1/2 study of 'JIN-A02', a Novel Oral 4th Generation EGFR TKI, at ESMO Asia 2023

SEOUL, South Korea, Dec. 5, 2023 /PRNewswire/ -- J INTS BIO announced that early results of the Phase 1/2 study of its novel, orally administered 4th generation EGFR-TKI 'JIN-A02' were presented at the ESMO Asia 2023 conference held inSingapore from 1st to 3rd December 2023.

2023-12-05 15:16 1193

Clarivate Expands Partnership with VeriSIM Life to Accelerate and De-risk Research and Drug Development

New AI-enabled, integrated workflow provides pharma and biotech companies with comprehensive R&D insights to help minimize late-stage failures during clinical trials LONDON, Dec. 5, 2023 /PRNewswire/ -- Clarivate Plc (NYSE:CLVT), a global leader in connecting people and organizations to intellig...

2023-12-05 15:00 1154

Insilico Medicine Announces First-in-Human Study for Orally PHD Inhibitor ISM5411 for Inflammatory Bowel Disease (IBD)

* ISM5411 is an oral, PHD-specific inhibitor that facilitates the treatment of IBD by inducing the expression of gut barrier protective genes. * ISM5411 is Insilico Medicine's fifth AI-driven drug program to enter clinical trials, with the first dose of healthy subjects completed inAustralia. ...

2023-12-05 06:00 1443

CARsgen's CT071 Received IND Clearance from the FDA for Treating Relapsed/Refractory Multiple Myeloma or Relapsed/Refractory Primary Plasma Cell Leukemia

SHANGHAI, Dec. 4, 2023 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on innovative CAR T-cell therapies for the treatment of hematologic malignancies and solid tumors, announces that the U.S. Food and Drug Administration (FDA) has granted Investiga...

2023-12-04 21:50 1145

Technoderma Medicines Completes Phase 1 Dose Escalation Clinical Trial of TDM-180935 for Atopic Dermatitis

CHENGDU, China, Dec. 4, 2023 /PRNewswire/ -- Technoderma Medicines, Inc. ("the Company"), a clinical stage biopharmaceutical company, is pleased to report that the Company has completed a Phase 1 clinical trial (NCT05525468) of TDM-180935 topical ointment for Atopic Dermatitis (AD). This first cl...

2023-12-04 21:13 1147

Abbisko Therapeutics Announced the Entry into a Licensing Agreement for Pimicotinib (ABSK021) with Merck

SHANGHAI, Dec. 4, 2023 /PRNewswire/ -- On 4 Dec. 2023, Abbisko Therapeutics announced that it has entered into a licensing agreement with Merck, a leading science and technology company headquartered in Darmstadt,Germany. Under the terms of the agreement, Merck will be granted an exclusive licens...

2023-12-04 21:05 1086

Mootral introduces new methane reduction technology, doubling efficacy using a well-known natural molecule

Mootral's new platform reduces methane emissions from cows by 50% and can be delivered to both housed and grazing cattle, vastly increasing the opportunity to reduce methane emissions globally LONDON, Dec. 4, 2023 /PRNewswire/ -- Mootral, a British biotech company, announces it has completed the...

2023-12-04 20:00 1477

Latest Updates of Viva's Portfolio Companies

HONG KONG, Dec. 4, 2023 /PRNewswire/ -- Even with the ever-changing situation, technological innovation is still the most critical component for biopharmaceutical companies' long-term development. This continuous innovation keeps companies up to date and promotes the evolution of R&D and the succ...

2023-12-04 17:55 1471

Supercell Acquires Exclusive Licensing from Japanese Immunotherapy Leader for Advanced NK Cell Treatment Technology

TAIPEI, Dec. 4, 2023 /PRNewswire/ --  Supercell Biotechnology Corporation commemorates the first anniversary of rebranding from previously-called SinoCell Technologies, due to the company's capital increase by RMT Holding Group. Demonstrating the strategic move at the Healthcare+ Expo Taiwan, the...

2023-12-04 16:39 1363
1 ... 25262728293031 ... 280